{"id":"acadesine","rwe":[],"tags":[{"label":"acadesine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C01EB13","category":"atc"},{"label":"Active","category":"status"}],"phase":"discontinued","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"arasine","offLabel":[],"synonyms":["aminoimidazole carboxamide ribonucleoside","5-aminoimidazole-4-carboxamide riboside","acadesine","arasine"],"timeline":[],"brandName":"Arasine","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"acadesine","explanation":"Think of Arasine like a messenger that helps the heart work better. It increases the levels of adenosine, a natural substance that helps to relax blood vessels and improve blood flow to the heart. This can help to reduce the risk of heart damage during times of stress or low blood flow.","oneSentence":"Arasine works by increasing the levels of adenosine in the body, which helps to improve cardiac function and reduce ischemia.","technicalDetail":"Arasine acts as an adenosine-generating agent, which increases the levels of adenosine in the body through the deamination of AMP to IMP, thereby exerting its cardioprotective effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/37","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ACADESINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACADESINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:21:02.842768","biosimilars":[],"competitors":[{"drugName":"camphor","drugSlug":"camphor","fdaApproval":"","relationship":"same-class"},{"drugName":"indomethacin","drugSlug":"indomethacin","fdaApproval":"1965-06-10","patentExpiry":"Apr 23, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ubidecarenone","drugSlug":"ubidecarenone","fdaApproval":"","relationship":"same-class"},{"drugName":"adenosine","drugSlug":"adenosine","fdaApproval":"1989-10-30","genericCount":15,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ibuprofen","drugSlug":"ibuprofen","fdaApproval":"1974-09-19","patentExpiry":"Sep 30, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ivabradine","drugSlug":"ivabradine","fdaApproval":"2015-04-15","patentExpiry":"Feb 22, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ranolazine","drugSlug":"ranolazine","fdaApproval":"2006-01-27","patentExpiry":"Jan 24, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"regadenoson","drugSlug":"regadenoson","fdaApproval":"2008-04-10","patentExpiry":"Feb 2, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"mavacamten","drugSlug":"mavacamten","fdaApproval":"2022-04-28","patentExpiry":"Jun 19, 2034","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"acadesine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"camphor","brandName":"camphor","genericName":"camphor","approvalYear":"","relationship":"same-class"},{"drugId":"indomethacin","brandName":"indomethacin","genericName":"indomethacin","approvalYear":"1965","relationship":"same-class"},{"drugId":"ubidecarenone","brandName":"ubidecarenone","genericName":"ubidecarenone","approvalYear":"","relationship":"same-class"},{"drugId":"adenosine","brandName":"adenosine","genericName":"adenosine","approvalYear":"1989","relationship":"same-class"},{"drugId":"ibuprofen","brandName":"ibuprofen","genericName":"ibuprofen","approvalYear":"1974","relationship":"same-class"},{"drugId":"ivabradine","brandName":"ivabradine","genericName":"ivabradine","approvalYear":"2015","relationship":"same-class"},{"drugId":"ranolazine","brandName":"ranolazine","genericName":"ranolazine","approvalYear":"2006","relationship":"same-class"},{"drugId":"regadenoson","brandName":"regadenoson","genericName":"regadenoson","approvalYear":"2008","relationship":"same-class"},{"drugId":"mavacamten","brandName":"mavacamten","genericName":"mavacamten","approvalYear":"2022","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01813838","phase":"PHASE1,PHASE2","title":"GFM-Acadesine: A Phase I-II Trial of Acadesine","status":"TERMINATED","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2013-06","conditions":["SMD"],"enrollment":5,"completionDate":"2015-06"},{"nctId":"NCT00872001","phase":"PHASE3","title":"The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633 AM1)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04","conditions":["Coronary Artery Bypass","Myocardial Infarction","Ventricular Dysfunction, Left","Stroke","Cardiopulmonary Bypass"],"enrollment":3080,"completionDate":"2010-10"},{"nctId":"NCT00559624","phase":"PHASE1,PHASE2","title":"Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients","status":"COMPLETED","sponsor":"Advancell - Advanced In Vitro Cell Technologies, S.A.","startDate":"2007-12","conditions":["Leukemia, B-Cell, Chronic"],"enrollment":40,"completionDate":"2010-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"53IEF47846","CHEBI":"CHEBI:28498","INN_ID":"6758","UMLSCUI":"C0051027","ChEMBL_ID":"CHEMBL1551724","KEGG_DRUG":"D02742","DRUGBANK_ID":"DB04944","PUBCHEM_CID":"17513","IUPHAR_LIGAND_ID":"5133","MESH_SUPPLEMENTAL_RECORD_UI":"C011651"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"10%"},"publicationCount":0,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C01EB13","allCodes":["C01EB13"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arasine (ACADESINE) is a small molecule drug in the acadesine class, originally developed by but currently owned by . It is used to treat , although its exact target is unknown. The commercial status of Arasine is unclear, as it is unknown whether it is patented or has generic manufacturers. Key safety considerations include its low bioavailability of 10%. Arasine's FDA approval status and off-patent status are also unknown.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}